Market Cap
US$57.1m
Last Updated
2020/04/04 13:08 UTC
Data Sources
Company Financials +
Executive Summary
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment of cancer.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Mediocre balance sheet and slightly overvalued.
Share Price & News
How has Sesen Bio's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SESN's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-8.2%
SESN
2.0%
US Biotechs
-2.8%
US Market
1 Year Return
-48.6%
SESN
-1.3%
US Biotechs
-15.9%
US Market
Return vs Industry: SESN underperformed the US Biotechs industry which returned -0.9% over the past year.
Return vs Market: SESN underperformed the US Market which returned -15.1% over the past year.
Shareholder returns
| SESN | Industry | Market | |
|---|---|---|---|
| 7 Day | -8.2% | 2.0% | -2.8% |
| 30 Day | -39.5% | -8.0% | -18.8% |
| 90 Day | -49.4% | -4.6% | -24.0% |
| 1 Year | -48.6%-48.6% | -0.5%-1.3% | -14.2%-15.9% |
| 3 Year | -73.8%-73.8% | 13.3%10.5% | 9.9%2.8% |
| 5 Year | -95.0%-95.0% | -7.7%-12.0% | 27.2%13.3% |
Price Volatility Vs. Market
How volatile is Sesen Bio's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
Is Sesen Bio (NASDAQ:SESN) In A Good Position To Deliver On Growth Plans?1 month ago | Simply Wall St
Do Institutions Own Sesen Bio, Inc. (NASDAQ:SESN) Shares?2 months ago | Simply Wall St
Introducing Sesen Bio (NASDAQ:SESN), The Stock That Tanked 92%Valuation
Is Sesen Bio undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SESN ($0.52) is trading below our estimate of fair value ($24.2)
Significantly Below Fair Value: SESN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: SESN is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: SESN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SESN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SESN has negative assets, so we can't compare its PB Ratio to the US Biotechs industry average.
Next Steps
Future Growth
How is Sesen Bio forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
58.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SESN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SESN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SESN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if SESN's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if SESN's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SESN's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Sesen Bio performed over the past 5 years?
-25.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SESN is currently unprofitable.
Growing Profit Margin: SESN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SESN is unprofitable, and losses have increased over the past 5 years at a rate of -25.6% per year.
Accelerating Growth: Unable to compare SESN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SESN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).
Return on Equity
High ROE: SESN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Next Steps
Financial Health
How is Sesen Bio's financial position?
Financial Position Analysis
Short Term Liabilities: SESN has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: SESN has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: SESN is debt free.
Reducing Debt: SESN's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Inventory Level: SESN has a low level of unsold assets or inventory.
Debt Coverage by Assets: SESN has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SESN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: SESN has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of -1.1% each year.
Next Steps
Dividend
What is Sesen Bio's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SESN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate SESN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SESN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SESN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SESN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.3yrs
Average management tenure
CEO
Thomas Cannell (57yo)
1.67s
Tenure
US$2,009,874
Compensation
Dr. Thomas R. Cannell, DVM, is President, Chief Executive Officer and Director at Sesen Bio, Inc. since August 7, 2018. He served as Chief Operating Officer of Orexigen Therapeutics, Inc. since June 8, 201 ...
CEO Compensation Analysis
Compensation vs Market: Thomas's total compensation ($USD2.01M) is above average for companies of similar size in the US market ($USD618.59K).
Compensation vs Earnings: Insufficient data to compare Thomas's compensation with company performance.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.67yrs | US$2.01m | no data | |
| Chief Medical Officer | 1.33yrs | US$709.28k | 0.018% $10.4k | |
| Co-Founder | no data | no data | no data | |
| Chief Financial Officer | 0.67yr | no data | no data | |
| Corporate Controller & Principal Accounting Officer | 0.67yr | no data | 0.029% $16.7k | |
| Chief Technology Officer | 3.17yrs | no data | no data | |
| Vice President of Corporate Strategy & Investor Relations | no data | no data | no data | |
| General Counsel & Corporate Secretary | 0.67yr | no data | no data | |
| Senior Vice President of Clinical Development | 2.92yrs | no data | no data | |
| Head of Research | no data | no data | no data |
1.3yrs
Average Tenure
50yo
Average Age
Experienced Management: SESN's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.67yrs | US$2.01m | no data | |
| Independent Director | 6.17yrs | US$130.30k | 0.032% $18.1k | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Independent Director | 6.17yrs | US$133.43k | no data | |
| Independent Chairman of the Board | 0.17yr | US$113.78k | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Independent Director | 0.17yr | no data | 0.0030% $1.7k | |
| Independent Director | 0.17yr | no data | 0.0030% $1.7k | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data |
0.9yrs
Average Tenure
56.5yo
Average Age
Experienced Board: SESN's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 47.2%.
Top Shareholders
Company Information
Sesen Bio, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Sesen Bio, Inc.
- Ticker: SESN
- Exchange: NasdaqGM
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$57.084m
- Shares outstanding: 109.99m
- Website: https://www.sesenbio.com
Number of Employees
Location
- Sesen Bio, Inc.
- 245 First Street
- Suite 1800
- Cambridge
- Massachusetts
- 2142
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SESN | NasdaqGM (Nasdaq Global Market) | Yes | Common Stock | US | USD | Feb 2014 |
| PCBK | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Feb 2014 |
| 0IFZ | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Feb 2014 |
Biography
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment of cancer. The company’s lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a systemically-administered product candidate, which is in Phase I/II clinical trials for use in the treatment of various types of EpCAM-positive solid tumors. It is also developing Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of high-risk NMIBC; and Vicinium in combination with AstraZeneca’s checkpoint inhibitor that is in Phase I/IIa clinical trials for the treatment of squamous cell carcinoma of the head and neck. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/04/04 13:08 |
| End of Day Share Price | 2020/04/03 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.